50 / 83
S
asso
GRS
et
al
.
528
R
ev
A
ssoc
M
ed
B
ras
2015; 61(6):524-529
xes: (Osteoprotegerin OR Osteoclastogenesis Inhibitory
Factor OR Receptors, Tumor Necrosis Factor, Member 11b
OR Tumor Necrosis Factor Receptor Superfamily, Mem-
ber 11b OR FDCR-1 Protein OR FDCR 1 Protein OR OCIF
Protein OR Follicular Dendritic Cell-Derived Receptor-1)
AND (Bones AND Bone OR Bones AND Bone Tissue OR
Bones OR Bone Tissue OR Cardiovascular Diseases).
Resultados:
a OPG está presente em vários órgãos e une-
-se a dois ligantes: o fator nuclear kB (RANKL), relaciona-
do com a diferenciação dos osteoclastos, e o fator de ne-
crose tumoral, relacionado ao ligante indutor de
apoptose (TRAIL). Assim, a OPG inibe os efeitos da regu-
lação do fator nuclear kB na inflamação e nos sistemas
esquelético e vascular, prevenindo a apoptose induzida
pelo TRAIL, estando relacionada com a preservação do
tecido ósseo.
Conclusão:
um conhecimento mais aprofundado sobre
os mecanismos envolvidos na associação entre os níveis
séricos da OPG, integridade óssea e doenças cardiovascu-
lares podem proporcionar dados importantes para futu-
ras intervenções terapêuticas.
Palavras-chave:
osteoprotegerina, ligante RANK, recep-
tores do ligante indutor de apoptose relacionado a TNF,
osso e ossos.
R
eferences
1.
Song R, Gu J, Liu X, Zhu J, Wang Q, Gao Q, et al. Inhibition of osteoclast
bone resorption activity through osteoprotegerin-induced damage of the
sealing zone. Int J Mol Med. 2014; 34:856-62.
2.
Sharma A, Einstein AJ, Vallakati A, Arbab-Zadeh A, Walker MD, Mukherjee
D, et al. Risk of atrial fibrillation with use of oral and intravenous
bisphosphonates. Am J Cardiol. 2014; 113:1815-21.
3.
Bhutani G, Gupta MC. Emerging therapies for the treatment of osteoporosis.
J Midlife Health. 2013; 4:147-52.
4.
Miyazaki T, Tokimura F, Tanaka S. A review of denosumab for the treatment
of osteoporosis. Patient Prefer Adherence. 2014; 8:463-71.
5.
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al.
Osteoprotegerin: a novel secreted protein involved in the regulation of bone
density. Cell. 1997; 89:309-19.
6.
Baud’huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C,
Maillasson M, et al. Osteoprotegerin: multiple partners for multiple functions.
Cytokine Growth Factor Rev. 2013; 24:401-9.
7.
Benslimane-Ahmim Z, Poirier F, Delomenie C, Lokajczyk A, Grelac F, Galy-
Fauroux I, et al. Mechanistic study of the proangiogenic effect of
osteoprotegerin. Angiogenesis. 2013; 16:575-93.
8.
Standal T, Seidel C, Hjertner Ø, Plesner T, Sanderson RD, Waage A, et al.
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma
cells. Blood. 2002; 100:3002-7.
9. Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, Patsch JR,
et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human
peripheral blood monocytes. J Clin Endocrinol Metab. 2005; 90:2964-71.
10.
Krämer HH, Hofbauer LC, Szalay G, Breimhorst M, Eberle T, Zieschang K,
et al. Osteoprotegerin: a new biomarker for impaired bone metabolism in
complex regional pain syndrome? Pain. 2014; 155:889-95.
11.
Hyseni A, Roest M, Braun SL, Barendrecht AD, de Groot PG, Ndrepepa G,
et al. Chronic dysfunction of the endothelium is associated with mortality
in acute coronary syndrome patients. Thromb Res. 2013; 131:198-203.
12. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased
amounts in diabetes and modifiable synthesis from vascular smooth muscle
cells by insulin and TNF-alpha. Diabetologia. 2005; 48:561-8.
13. Väänänen K. Mechanism of osteoclast mediated bone resorption--rationale
for the design of new therapeutics. Adv Drug Deliv Rev. 2005; 57:959-71.
14.
Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T
cells regulate bone loss and joint destruction in adjuvant arthritis through
osteoprotegerin ligand. Nature. 1999, 402:304-9.
15. Ominsky MS, Kostenuik PJ, Cranmer P, Smith SY, Atkinson JE. The RANKL
inhibitor OPG-Fc increases cortical and trabecular bone mass in young
gonad-intact cynomolgus monkeys. Osteoporos Int. 2007; 18:1073-82.
16. Garnero P. New developments in biological markers of bone metabolism
in osteoporosis. Bone. 2014; 66C:46-55.
17.
Mencej-Bedra
č
S, Zupan J, Mlakar SJ, Zavratnik A, Prezelj J, Marc J. Raloxifene
pharmacodynamics is influenced by genetic variants in the RANKL/RANK/
OPG system and in the Wnt signaling pathway. Drug Metabol Drug Interact.
2014; 29:111-4.
18. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal
osteoporosis. J Steroid Biochem Mol Biol. 2014; 142:155-70.
19.
Kobayashi Y, Hashimoto F, Miyamoto H, Kanaoka K, Miyazaki-Kawashita
Y, Nakashima T, et al. Forceinduced osteoclast apoptosis in vivo is
accompanied by elevation in transforming growth factor b and
osteoprotegerin expression. J Bone Miner Res. 2000; 15:1924-34.
20. Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, et al. One
year of transgenic overexpression of osteoprotegerin in rats suppressed bone
resorption and increased vertebral bone volume, density, and strength. J
Bone Miner Res. 2009; 24:1234-46.
21.
Papaefthymiou MA, Bakoula C, Sarra A, Papassotiriou I, Chrousos GP,
Bacopoulou F. Influence of hormonal parameters, bone mineral density
and bone turnover on fracture risk in healthy male adolescents: a case control
study. J Pediatr Endocrinol Metab. 2014; 27:685-92.
22.
Smith BB, Cosenza ME, Mancini A, Dunstan C, Gregson R, Martin SW, et
al. A toxicity profile of osteoprotegerin in the cynomolgus monkey. Int J
Toxicol. 2003; 22:403-12.
23.
Hamdy NA. Osteoprotegerin as a potential therapy for osteoporosis. Curr
Rheumatol Rep. 2006; 8:50-4.
24.
Lampropoulos CE, Papaioannou I, D’Cruz DP. Osteoporosis a risk factor
for cardiovascular disease? Nat Rev Rheumatol. 2012; 8:587-98.
25.
Montagnana M1, Lippi G, Danese E, Guidi GC. The role of osteoprotegerin
in cardiovascular disease. Ann Med. 2013; 45:254-64.
26.
Buso G, Faggin E, Pauletto P, Rattazzi M. Osteoprotegerin in cardiovascular
disease: ally or enemy? Curr Pharm Des. 2014; 20:5862-9.
27.
Hakimi M, Hyhlik-Dürr A, von Au A, Betz M, Demirel S, Dihlmann S, et al.
The expression of glycophorin A and osteoprotegerin is locally increased in
carotid atherosclerotic lesions of symptomatic compared to asymptomatic
patients. Int J Mol Med. 2013; 32:331-8.
28.
Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma
concentrations correlate with severity of peripheral artery disease.
Atherosclerosis. 2005; 182:175-80.
29.
Ueland T, Yndestad A, Dahl CP, Gullestad L, Aukrust P. TNF revisited:
osteoprotegerin and TNF-related molecules in heart failure. Curr Heart Fail
Rep. 2012; 9:92-100.
30. Asanuma YF, Shimada Y, Kouzu N, Yokota K, Nakajima K, Sato K, et al.
Serum osteoprotegerin concentration is associated with carotid
atherosclerotic plaque in patients with rheumatoid arthritis. Mod Rheumatol.
2013; 23:269-75.
31. Aksu F, Ozçelik F, Kunduracilar H, Barutçu A, Yel M, Umit EGet al. The
relation between the levels of osteoprotegerin and the degree of coronary
artery disease in patients with acute coronary syndrome and stable angina
pectoris. Kardiol Pol. 2014; 72(1):34-41.
32.
Straface G, Biscetti F, Pitocco D, Bertoletti G, Misuraca M, Vincenzoni C,
et al. Assessment of the genetic effects of polymorphisms in the
osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and
carotid plaque vulnerability. Stroke. 2011; 42:3022-8.
33.
Biscetti F, Straface G, Giovannini S, Santoliquido A, Angelini F, Santoro
L, et al. Association between TNFRSF11B gene polymorphisms and
history of ischemic stroke in Italian diabetic patients. Hum Genet. 2013;
132:49-55.
34.
Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al.
Osteoprotegerin deficient mice develop early onset osteoporosis and arterial
calcification. Genes Dev. 1998; 12:1260-8.